A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium

Background: Currently, nanoliposomal irinotecan (nal-IRI) + 5-fluorouracil/folinic acid (5-FU/LV) is the only approved second-line treatment for patients suffering from metastatic pancreatic ductal adenocarcinoma (mPDAC). However, also other chemotherapeutic regimens are used in this setting and due...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Medical Oncology
Main Authors:	Lise Verbruggen, Lisa Verheggen, Greetje Vanhoutte, Catherine Loly, Willem Lybaert, Ivan Borbath, Philippe Vergauwe, Koen Hendrickx, Celine Debeuckelaere, Amy de Haar-Holleman, Jean-Luc Van Laethem, Marc Peeters
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-08-01
Online Access:	https://doi.org/10.1177/17588359231181500